Literature DB >> 7515300

Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation.

C Shimazaki1, N Oku, H Uchiyama, N Yamagata, T Tatsumi, T Hirata, E Ashihara, K Okawa, H Goto, T Inaba.   

Abstract

To examine the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery after high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT), 20 patients with hematologic malignancies were divided into two groups. One group was given G-CSF at a daily dose of 50 micrograms/m2 subcutaneously, the other received no G-CSF. Neutrophil recovery was accelerated in the G-CSF treated patients and exceeded 0.5 x 10(9)/l at a median of 10 days post-PBPCT compared with 14 days in the control group (p < 0.01). This reduction led to a decrease in antibiotic use and a trend toward fewer febrile days in the G-CSF treated group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515300

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Improvement of hematologic recovery after high-dose intensification using peripheral blood progenitor cells (PBPC) mobilized by chemotherapy and GM-CSF.

Authors:  T Lamy; B Drenou; I Grulois; C Leberre; C Dauriac; L Amiot; M Godard; R Fauchet; P Y LePrise
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

2.  High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration.

Authors:  P Benedetti Panici; L Pierelli; G Scambia; M L Foddai; M G Salerno; G Menichella; M Vittori; F Maneschi; U Caracussi; R Serafini; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

Authors:  S M Lee; J A Radford; L Dobson; T Huq; W D Ryder; R Pettengell; G R Morgenstern; J H Scarffe; D Crowther
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Intensification of chemotherapy for the treatment of solid tumours: feasibility of a 3-fold increase in dose intensity with peripheral blood progenitor cells and granulocyte colony-stimulating factor.

Authors:  S Leyvraz; N Ketterer; L Perey; J Bauer; P Vuichard; J P Grob; P Schneider; V von Fliedner; F Lejeune; F Bachmann
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.